Last reviewed · How we verify
NCT05645016
Tailoring Overdose Education for Black Churches
NA trial testing COEST in Opioid Overdose. Withdrawn.
30 December 2026
Quick facts
| Lead sponsor | New York State Psychiatric Institute |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Start date | 1 April 2023 |
| Primary completion | 30 December 2026 |
| Estimated completion | 30 March 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- COEST
Conditions studied
- Opioid Overdose — all drugs for Opioid Overdose →
Sponsor
New York State Psychiatric Institute
Who can join
18 and older, any sex, with Opioid Overdose. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Church-based interventions are culturally acceptable, reduce access barriers, and can be brought to scale in under-resourced communities. For Overdose Education and Naloxone Distribution (OEND) to be efficacious in Black churches, tailoring may be needed. For this audience, standard OEND curricula may need to be adapted to their level of knowledge of substance use disorders (SUDs), and limited general mental health literacy, and specifically address stigma related to SUDs and medications for opioid use disorder (MOUD). Finally, a tailored implementation strategy may need to address contextual variations (e.g., denomination and membership size) across churches. The proposed pilot study aims to identify the socio-cultural modifications that will be needed to adapt our previously developed training (i.e., COEST) to target Black communities of faith. In a pilot randomized controlled trial (RTC) of adapted COEST in a stepped-wedge design.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05645016
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Opioid Overdose
Currently open trials in the same condition.
- NCT07079241 — A Model to Save Lives Through a Volunteer First Responder Service Providing Antidote Treatment in Opioid Overdose · NA · recruiting
- NCT06806163 — Machine-Learning Prediction and Reducing Overdoses With EHR Nudges · NA · recruiting
- NCT06593093 — A Bundled Intervention · Phase 1, PHASE2 · recruiting
- NCT06429436 — Vending Machine Naloxone Distribution for Your Community (VENDY) · Phase 4 · recruiting
- NCT05877118 — Improving Availability of Intranasal Naloxone · NA · recruiting
Other New York State Psychiatric Institute trials
Trials by the same sponsor.
- NCT05416658 — Shared Decision Making for Antipsychotic Medications · NA · not yet recruiting
- NCT07423546 — A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia · Phase 1, PHASE2 · not yet recruiting
- NCT05339256 — Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual · Phase 2 · not yet recruiting
- NCT05563948 — Repeated Administration of Cannabis Varying in THC and CBD · Phase 2 · suspended
- NCT06977308 — A Multimodal Imaging Study of Dopamine in Early Psychosis · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05645016 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New York State Psychiatric Institute
- Last refreshed: 2 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05645016.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing